ALKS Alkermes Plc

USD 27.00 0.00 ( 0.00%)
Icon

Alkermes Plc (ALKS) Financial Statements

COMMON STOCK | Drug Manufacturers - Specialty & Generic | NSD
stockTargetAdvisor

Buy

Average Analyst
Rating
stockTargetAdvisor

Buy

Top Analyst
Rating
stockTargetAdvisor

Bullish

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 27.00

0.00 (0.00%)

USD 5.40B

1.74M

USD 37.78(+39.92%)

USD 28.50 (+5.56%)

Icon

ALKS

Alkermes Plc (USD)
COMMON STOCK | NSD
USD 27.00
0.00 ( 0.00%)

Alkermes Plc (ALKS) Annual Income Statement (USD)

ALKS Quarterly Financials (USD)

Frequently Asked Questions About Alkermes Plc (ALKS) Stock

Alkermes Plc's (ALKS) last reported annual revenue was USD 1.56 Billion.

Alkermes Plc's (ALKS) annual revenue growth rate based on the revenue reported in the past 5 years is : 5.87%

Alkermes Plc's(ALKS) is profitable as of its last reported annual financials.

The net profit margin for Alkermes Plc's(ALKS) from its laster reported year is 23.57%

The return on equity (ROE) for Alkermes Plc's(ALKS) from its last reported annual financials is : 27.90%

The return on assets (ROA) for Alkermes Plc's(ALKS) from its last reported annual financials is : 12.54%

The return on invested capital (ROIC) for Alkermes Plc's(ALKS) from its last reported annual financials is : 23.60%

The Debt to Equity ratio for Alkermes Plc's(ALKS) from its last reported annual financials is : 0.00%

The dividend yield for Alkermes Plc's(ALKS) from its laster reported year is 0.00%

Alkermes Plc's(ALKS) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...